替吉奥联合多西他赛方案治疗进展期胃癌的临床观察  

Clinical obeservation Of S-1 combined with docetaxel in the treatment of patients with advanced gastric cancer

作　　者：韩守恒[1] 戴文香[1] 伍尤华[1] 

机构地区：[1]南华大学附属第一医院肿瘤内科,湖南衡阳421001

出　　处：《湘南学院学报（医学版）》2012年第2期23-25,共3页Journal of Xiangnan University（Medical Sciences）

摘　　要：目的观察替吉奥联合多西他赛治疗进展期胃癌的近期疗效和毒副反应。方法 44例进展期胃癌患者采用以下方法化疗:替吉奥胶囊每天80 mg/m^2,分2次,餐后口服,第1～14天;多西他赛75 mg/m^2,第1天,静脉滴注2～3 h,21d为1个周期,至少完成2个周期。评价客观疗效和不良反应。结果 44例均可以评价疗效。CR 3例(6.8%),PR 18例(40.9%),SD 14例(31.8%),PD 9例(20.5%),RR 47.7%,DCR 79.5%。中位疾病进展时间为7.2月,中位生存期为11.3月。不良反应主要是骨髓抑制、胃肠道反应、脱发及口腔黏膜炎。结论替吉奥联合多西他赛方案治疗进展期胃癌的疗效较好,不良反应可以耐受,值得进一步研究应用。Objective To observe the efficacy and toxicity of S - 1 plus docetaxel in the treatment of advanced gastric cancer patients. Methods 44 patients with advanced gastric cancer were treated with chemotherapy of intra- venous S - lcapsule 80 mg/m^2 twice daily for 14 days and docetaxel 75 mg/in2 on 1st day. The chemotherapy was repeated every 21 days. All patients received 2 cycles at least. Efficacy and toxicity were evaluated according to the RECIST 1.1 standard. Results A total of 44 patients can be evaluated. 3 （6.8 % ） patients got complete remission （CR）, 18 （40.9 %） partial remission（PR）, 14（31.8 %） stable disease （SD）, and 9 （20.5 %） progression disease （PD）. The total response rate was 47.7%. The disease control rate （DCR） was 79.5 %. The median time to progression （mTIP） was 7.2 months. The median survival time （MST） was 11.3 months. The major toxic reactions included leucopenia, nausea, vomiting and neurosensory abnormality. Conclusion S- 1 combined with docetaxel is effective and tolerable in the treatment of patients with advanced gastric cancer.

关 键 词：胃癌 替吉奥 多西他赛 

分 类 号：R735.2[医药卫生—肿瘤]